ABSTRACT
Cancer-related fatigue (CRF) is a common and distressing symptom of cancer and its treatments that may persist for years following treatment completion in approximately one-third of cancer survivors. Despite its high prevalence, little is known about the pathophysiology of CRF. Using a comprehensive group of physiological and psychosocial variables, the aim of the present study was to identify correlates of CRF in a heterogenous group of cancer survivors. Ninety-three cancer survivors (51 fatigued, 42 non-fatigued, with grouping based on validated cut-off scores derived from The Functional Assessment of Chronic Illness Therapy - Fatigue scale) completed assessments of performance fatigability (i.e. the change in maximal force-generating capacity, contractile function and capacity of the central nervous system to activate muscles caused by cycling exercise), cardiopulmonary exercise testing, venous blood samples for whole blood cell count and inflammatory markers and body composition. Participants also completed questionnaires measuring demographic, treatment-related, and psychosocial variables. The results showed that performance fatigability (decline in muscle strength during exercise), time-to-task-failure, peak oxygen uptake 
, tumor necrosis factor-α (TNF-α), body fat percentage and lean mass index were associated with CRF severity. Performance fatigability, 
, TNF-α and age explained 35% of the variance in CRF severity. Furthermore, those with clinically-relevant CRF reported more pain, more depressive symptoms, less social support, and were less physically active than non-fatigued cancer survivors. Given the association between CRF and numerous physical activity related measures, including performance fatigability, cardiorespiratory fitness, and anthropometric measures, the present study identifies potential biomarkers by which the mechanisms underpinning the effect of physical activity interventions on CRF can be investigated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research is funded by the Canadian Cancer Society (grant #704208-1)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for all procedures was obtained by the Conjoint Health Research Ethics Board and the Health Research Ethics Board of Alberta Cancer Committee (REB14-0398 and HREBA.CC-16-10-10, respectively)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
data available on request
